Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRX-106 in Mild to Moderate Ulcerative Colitis
2016-000509-35Phase 2Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of OPRX-106 in autoimmune colitis (2 arms), sponsored by Protalix BioTherapeutics. Primary endpoints: Pharmacokinetic endpoints and Safety endpoints. Started Aug 2016; status: completed.
02
Drugs
OPRX-106
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000509-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000509-35.